Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Core Viewpoint - Alterity Therapeutics has appointed Abby Macnish Niven as Company Secretary following her role as Chief Financial Officer, effective November 18, 2024, succeeding Phillip Hains [1][2]. Group 1: Management Changes - Abby Macnish Niven was appointed as CFO on September 30, 2024, and has extensive experience in private wealth management with firms such as ANZ, UBS, and Ord Minett [3]. - Ms. Macnish Niven will be responsible for communications between the Company and ASX as per ASX Listing Rule 12.6 [4]. Group 2: Company Overview - Alterity Therapeutics is a clinical stage biotechnology company focused on developing treatments for neurodegenerative diseases, with its lead asset ATH434 currently evaluated in two Phase 2 clinical trials for Multiple System Atrophy [5]. - The Company is based in Melbourne, Australia, and San Francisco, California, and has a drug discovery platform aimed at creating patentable compounds for neurological diseases [5].